Scientists have discovered that bacteria commonly found in cows produce signaling molecules that can effectively treat antibiotic-resistant infections, offering a promising weapon against the growing threat of methicillin-resistant Staphylococcus aureus (MRSA).
The finding could help address one of medicine’s most pressing challenges: bacterial infections that no longer respond to conventional antibiotics.
Researchers from the University of Copenhagen conducted the largest mapping to date of bacterial communication networks, revealing how different Staphylococcus species interfere with each other’s ability to coordinate attacks on human tissue. Their work identified signaling molecules from Staphylococcus simulans—a species typically found on cattle—that can disrupt MRSA’s communication systems as effectively as standard antibiotic treatments.
Bacterial Communication Networks
Like people talking on walkie-talkies, bacteria communicate using specific “frequencies” or signaling molecules to coordinate group behavior. When pathogenic bacteria like MRSA infect wounds, they use these chemical signals to organize their attack. However, other bacterial species can jam these communications, weakening the pathogens’ ability to cause disease.
“With our mapping, we can identify which signaling molecules are most effective against MRSA,” said Christian Adam Olsen, professor at the Department of Drug Design and Pharmacology at the University of Copenhagen. “We found that a signal from another Staphylococcus variant, Staphylococcus simulans, was very potent against S. aureus. Originally, the signaling molecule was isolated from a bacterial strain from a cow, but it is also present on goats, horses and humans.”
The research team tested 35 different signaling molecules from 21 bacterial species, creating a comprehensive map of 280 bacterial interactions. They discovered that molecules from animal-associated bacteria were generally more potent inhibitors than those from human-associated species.
Testing Against MRSA
The researchers tested their most promising candidate—S. simulans signaling molecules—in laboratory and animal studies. Key findings included:
- A single dose matched the effectiveness of daily antibiotic ointment treatments in mice
- Bacteria showed no signs of developing resistance after 15 days of exposure
- The treatment reduced bacterial load in infected skin by approximately 60-fold
- Signaling molecules could deactivate already-active MRSA infections
In mouse studies, animals treated with S. simulans signaling molecules showed significant reduction in skin lesion size after 48 and 96 hours compared to untreated controls. The treatment performed comparably to fusidic acid, a standard antibiotic ointment.
“In the experiment, we showed that with a single dose of this signaling molecule, the mice could overcome an MRSA skin infection just as effectively as mice treated daily with an antibiotic ointment,” said postdoc Benjamin Svejdal Sereika-Bejder, who contributed to the study.
Avoiding Resistance Development
Unlike antibiotics, which kill bacteria and create evolutionary pressure for resistance, these signaling molecules work by disrupting communication without being lethal. The bacteria survive but lose their ability to coordinate attacks on the host’s immune system.
“No one has previously tested whether staphylococci develop resistance towards treatment with these signaling molecules, as we see with antibiotics,” Sereika-Bejder explained. “In our experiments, we observed that under laboratory conditions, the bacteria did not develop resistance even after 15 days.”
The mechanism offers a crucial advantage over traditional antibiotics. Since the signaling molecules don’t kill bacteria, there’s less evolutionary pressure driving resistance development. The bacteria encounter similar molecules naturally in their environment, making resistance less likely to emerge.
Clinical Potential
The research, published in mBio, represents a significant step toward developing anti-virulence therapies—treatments that disarm pathogens rather than killing them. This approach could be particularly valuable for treating MRSA infections, which affect hundreds of thousands of people annually and resist many standard antibiotics.
The Copenhagen team used sophisticated techniques including native chemical ligation to identify and synthesize the bacterial signaling molecules. Their systematic approach revealed that bovine-associated bacteria produce some of the most potent inhibitors, with S. simulans molecules showing effectiveness at concentrations 400-fold lower than previously known inhibitors.
Early-phase clinical studies with similar bacterial communication inhibitors have shown promise in treating skin conditions like atopic dermatitis. The researchers suggest their findings could lead to treatments that work alongside existing antibiotics or serve as alternatives when resistance develops.
While the initial results focus on skin infections, the underlying principle could potentially address other MRSA-related conditions. The research opens possibilities for developing treatments that work by disrupting bacterial teamwork rather than engaging in an arms race with rapidly evolving pathogens.
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.